Importance of Efferocytosis in COVID-19 Mortality

References

• Brown CM, Vostok J, Johnson H, et al. Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings — Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1059–1062. doi:10.15585/mmwr.mm7031e2
   PubMed Web of Science ®Google Scholar
• Riemersma KK, Grogan BE, Amanda Kita-Yarbro GE, David H, O’Connor TC, Friedrich KMG. Shedding of infectious SARS-CoV-2 despite vaccination when the delta variant is prevalent - Wisconsin, July 2021. Prepr medRxiv. 2021. doi:10.1101/2021.07.31.21261387
   Google Scholar
• Musser JM, Christensen PA, Olsen RJ, et al. Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas. Prepr medRxiv. 2021. doi:10.1101/2021.07.19.21260808
   Google Scholar
• Kimura I, Kosugi Y, Wu J, et al. SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance. Prepr bioRxiv. 2021. doi:10.1016/j.celrep.2021.110218
   Google Scholar
• Evans JP, Liu S-L. Role of host factors in SARS-CoV-2 entry. J Biol Chem. 2021;297:100847. doi:10.1016/j.jbc.2021.100847
   Web of Science ®Google Scholar
• Bohan D, Van Ert H, Ruggio N, et al. Phosphatidylserine receptors enhance SARS-CoV-2 infection: AXL as a therapeutic target for COVID-19. Prepr bioRxiv. 2021. doi:10.1101/2021.06.15.448419
   Google Scholar
• Hoffmann M, Kleine-Weber H, Pöhlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell. 2020;78:779–784.e5. doi:10.1016/j.molcel.2020.04.022
   PubMed Web of Science ®Google Scholar
• Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci. 2020;117:11727–11734. doi:10.1073/pnas.2003138117
   PubMed Web of Science ®Google Scholar
• Johnson BA, Xie X, Bailey AL, et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature. 2021;591:293–299. doi:10.1038/s41586-021-03237-4
   PubMed Web of Science ®Google Scholar
• Azad GK, Khan PK. Variations in Orf3a protein of SARS-CoV-2 alter its structure and function. Biochem Biophys Rep. 2021;26:100933. doi:10.1016/j.bbrep.2021.100933
   PubMedGoogle Scholar
• Ren Y, Shu T, Wu D, et al. The ORF3a protein of SARS-CoV-2 induces apoptosis in cells. Cell Mol Immunol. 2020;17:881–883. doi:10.1038/s41423-020-0485-9
   PubMed Web of Science ®Google Scholar
• Narahari AK, Kreutzberger AJ, Gaete PS, et al. ATP and large signaling metabolites flux through caspase-activated Pannexin 1 channels. Elife. 2021;10. doi:10.7554/eLife.64787.
   Web of Science ®Google Scholar
• Yamashita A, Morikawa H, Tajima N, et al. Mechanisms underlying production and externalization of oxidized phosphatidylserine in apoptosis: involvement of mitochondria. Yonago Acta Med. 2012;55:11–20.
   Web of Science ®Google Scholar
• Birge RB, Boeltz S, Kumar S, et al. Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. Cell Death Differ. 2016;23:962–978. doi:10.1038/cdd.2016.11
   PubMed Web of Science ®Google Scholar
• Dayoub AS, Brekken RA. TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy. Cell Commun Signal. 2020;18:29. doi:10.1186/s12964-020-0521-5
   Web of Science ®Google Scholar
• Kumar S, Calianese D, Birge RB. Efferocytosis of dying cells differentially modulate immunological outcomes in tumor microenvironment. Immunol Rev. 2017;280:149–164. doi:10.1111/imr.12587
   Web of Science ®Google Scholar
• Karaji N, Sattentau QJ. Efferocytosis of pathogen-infected cells. Front Immunol. 2017;8. doi:10.3389/fimmu.2017.01863/full
   Web of Science ®Google Scholar
• Calianese DC, Birge RB. Biology of phosphatidylserine (PS): basic physiology and implications in immunology, infectious disease, and cancer. Cell Commun Signal. 2020;18:41. doi:10.1186/s12964-020-00543-8
   PubMed Web of Science ®Google Scholar
• Serizier SB, McCall K. Scrambled eggs: apoptotic cell clearance by non-professional phagocytes in the drosophila ovary. Front Immunol. 2017;8. doi:10.3389/fimmu.2017.01642/full
   Web of Science ®Google Scholar
• Moller-Tank S, Maury W. Phosphatidylserine receptors: enhancers of enveloped virus entry and infection. Virology. 2014;468–470:565–580. doi:10.1016/j.virol.2014.09.009
   PubMed Web of Science ®Google Scholar
• Vogt B, Führnrohr B, Müller R, Sheriff A. CRP and the disposal of dying cells: consequences for systemic lupus erythematosus and rheumatoid arthritis. Autoimmunity. 2007;40:295–298. doi:10.1080/08916930701358925
   PubMed Web of Science ®Google Scholar
• Sheriff A, Kayser S, Brunner P, Vogt B. C-reactive protein triggers cell death in ischemic cells. Front Immunol. 2021;12. doi:10.3389/fimmu.2021.630430/full
   Web of Science ®Google Scholar
• Zwaka TP, Hombach V, Torzewski J. C-reactive protein–mediated low density lipoprotein uptake by macrophages. Circulation. 2001;103:1194–1197. doi:10.1161/01.CIR.103.9.1194
   PubMed Web of Science ®Google Scholar
• DeBerge M, Zhang S, Glinton K, et al. Efferocytosis and outside-in signaling by cardiac phagocytes. links to repair, cellular programming, and intercellular crosstalk in heart. Front Immunol. 2017;8. doi:10.3389/fimmu.2017.01428/full
   Web of Science ®Google Scholar
• Torzewski J, Zimmermann O, Kayser S, et al. Successful treatment of a 39-year-old COVID-19 patient with respiratory failure by selective C-reactive protein apheresis. Am J Case Rep. 2021;22. doi:10.12659/AJCR.932964.
   Web of Science ®Google Scholar
• Ringel J, Ramlow A, Bock C, Sheriff A. Case report: c-reactive protein apheresis in a patient with COVID-19 and fulminant CRP increase. Front Immunol. 2021;12. doi:10.3389/fimmu.2021.708101/full
   Web of Science ®Google Scholar
• Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998;392:86–89. doi:10.1038/32183
   PubMed Web of Science ®Google Scholar
• Moyer TJ, Zmolek AC, Irvine DJ. Beyond antigens and adjuvants: formulating future vaccines. J Clin Invest. 2016;126:799–808. doi:10.1172/JCI81083
   PubMed Web of Science ®Google Scholar
• Silva MT. Secondary necrosis: the natural outcome of the complete apoptotic program. FEBS Lett. 2010;584:4491–4499. doi:10.1016/j.febslet.2010.10.046
   PubMed Web of Science ®Google Scholar
• Laforge M, Elbim C, Frère C, et al. Tissue damage from neutrophil-induced oxidative stress in COVID-19. Nat Rev Immunol. 2020;20:515–516. doi:10.1038/s41577-020-0407-1
   PubMed Web of Science ®Google Scholar
• Wang J, Li Q, Yin Y, et al. Excessive neutrophils and neutrophil extracellular traps in COVID-19. Front Immunol. 2020;11. doi:10.3389/fimmu.2020.02063/full
   Web of Science ®Google Scholar
• Sachet M, Liang YY, Oehler R. The immune response to secondary necrotic cells. Apoptosis. 2017;22:1189–1204. doi:10.1007/s10495-017-1413-z
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Moki T, Takizawa T, Shiratsuchi A, Nakanishi Y. Evidence for phagocytosis of influenza virus-infected, apoptotic cells by neutrophils and macrophages in mice. J Immunol. 2007;178:2448–2457. doi:10.4049/jimmunol.178.4.2448
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Hashimoto Y, Shiratsuchi A, Takizawa T, Nakanishi Y. Augmentation of fatality of influenza in mice by inhibition of phagocytosis. Biochem Biophys Res Commun. 2005;337:881–886. doi:10.1016/j.bbrc.2005.09.133
   Web of Science ®Google Scholar
• Tian L, Choi S-C, Lee H-N, et al. Enhanced efferocytosis by dendritic cells underlies memory T-cell expansion and susceptibility to autoimmune disease in CD300f-deficient mice. Cell Death Differ. 2016;23:1086–1096. doi:10.1038/cdd.2015.161
   Web of Science ®Google Scholar
• Cho K-J, Ishido S, Eisenlohr LC, Roche PA. Activation of dendritic cells alters the mechanism of MHC class II antigen presentation to CD4 T cells. J Immunol. 2020;204:1621–1629. doi:10.4049/jimmunol.1901234
   Web of Science ®Google Scholar
• Wrobel AG, Benton DJ, Xu P, et al. SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects. Nat Struct Mol Biol. 2020;27:763–767. doi:10.1038/s41594-020-0468-7
   Web of Science ®Google Scholar
• Yurdagul A, Doran AC, Cai B, Fredman G, Tabas IA. Mechanisms and consequences of defective efferocytosis in atherosclerosis. Front Cardiovasc Med. 2018;4. doi:10.3389/fcvm.2017.00086/full
   Web of Science ®Google Scholar
• Schwarz B, Sharma L, Roberts L, et al. Cutting edge: severe SARS-CoV-2 infection in humans is defined by a shift in the serum lipidome, resulting in dysregulation of eicosanoid immune mediators. J Immunol. 2021;206:329–334. doi:10.4049/jimmunol.2001025
   PubMed Web of Science ®Google Scholar
• Arienti S, Barth ND, Dorward DA, Rossi AG, Dransfield I. Regulation of apoptotic cell clearance during resolution of inflammation. Front Pharmacol. 2019;10. doi:10.3389/fphar.2019.00891/full
   Web of Science ®Google Scholar
• Sendama W. The effect of ageing on the resolution of inflammation. Ageing Res Rev. 2020;57:101000. doi:10.1016/j.arr.2019.101000
   Web of Science ®Google Scholar
• Doran AC, Yurdagul A, Tabas I. Efferocytosis in health and disease. Nat Rev Immunol. 2020;20:254–267. doi:10.1038/s41577-019-0240-6
   PubMed Web of Science ®Google Scholar
• Gooz M. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol. 2010;45:146–169. doi:10.3109/10409231003628015
   PubMed Web of Science ®Google Scholar
• Shalaby L, Thounaojam M, Tawfik A, et al. Role of endothelial ADAM17 in early vascular changes associated with diabetic retinopathy. J Clin Med. 2020;9:400. doi:10.3390/jcm9020400
   Web of Science ®Google Scholar
• Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature. 1997;385:729–733. doi:10.1038/385729a0
   PubMed Web of Science ®Google Scholar
• Patel VB, Clarke N, Wang Z, et al. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. J Mol Cell Cardiol. 2014;66:167–176. doi:10.1016/j.yjmcc.2013.11.017
   PubMed Web of Science ®Google Scholar
• Salem ESB, Grobe N, Elased KM. Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice. Am J Physiol Physiol. 2014;306:F629–39. doi:10.1152/ajprenal.00516.2013
   PubMed Web of Science ®Google Scholar
• Li R, Uttarwar L, Gao B, et al. High glucose up-regulates ADAM17 through HIF-1α in mesangial cells. J Biol Chem. 2015;290:21603–21614. doi:10.1074/jbc.M115.651604
   Web of Science ®Google Scholar
• Stepanova G. Biologia futura: is ADAM 17 the reason for COVID-19 susceptibility in hyperglycemic and diabetic patients? Biol Future. 2021;72:291–297. doi:10.1007/s42977-021-00092-2
   PubMedGoogle Scholar
• Menghini R, Fiorentino L, Casagrande V, Lauro R, Federici M. The role of ADAM17 in metabolic inflammation. Atherosclerosis. 2013;228:12–17. doi:10.1016/j.atherosclerosis.2013.01.024
   PubMed Web of Science ®Google Scholar
• Matthews J, Villescas S, Herat L, Schlaich M, Matthews V. Implications of ADAM17 activation for hyperglycaemia, obesity and type 2 diabetes. Biosci Rep. 2021;41. doi:10.1042/BSR20210029
   Web of Science ®Google Scholar
• le Roux CW. COVID-19 alters thinking and management in metabolic diseases. Nat Rev Endocrinol. 2021;17:71–72. doi:10.1038/s41574-020-00449-y
   Web of Science ®Google Scholar
• Finucane FM, Davenport C. Coronavirus and obesity: could insulin resistance mediate the severity of Covid-19 infection? Front Public Health. 2020;8. doi:10.3389/fpubh.2020.00184/full
   Web of Science ®Google Scholar
• Yang G, Cui M, Jiang W, Sheng J, Yang Y, Zhang X. Molecular switch in human diseases-disintegrin and metalloproteinases, ADAM17. Aging (Albany NY). 2021;13:16859–16872. doi:10.18632/aging.203200
   Google Scholar
• Wang Y, Herrera AH, Li Y, Belani KK, Walcheck B. Regulation of mature ADAM17 by redox agents for L-selectin shedding. J Immunol. 2009;182:2449–2457. doi:10.4049/jimmunol.0802770
   PubMed Web of Science ®Google Scholar
• Zipeto D, da Palmeira JF, Argañaraz GA, Argañaraz ER. ACE2/ADAM17/TMPRSS2 interplay may be the main risk factor for COVID-19. Front Immunol. 2020;11. Available from 10.3389/fimmu.2020.576745/full.
   Web of Science ®Google Scholar
• Sommer A, Bhakdi S, Reiss K. How membrane asymmetry regulates ADAM17 sheddase function. Cell Cycle. 2016;15:2995–2996. doi:10.1080/15384101.2016.1211449
   PubMed Web of Science ®Google Scholar
• Reiss K, Bhakdi S. The plasma membrane: penultimate regulator of ADAM sheddase function. Biochim Biophys Acta Mol Cell Res. 2017;1864:2082–2087. doi:10.1016/j.bbamcr.2017.06.006
   Web of Science ®Google Scholar
• Darabi M, Kontush A. Phosphatidylserine in atherosclerosis. Curr Opin Lipidol. 2016;27:414–420. doi:10.1097/MOL.0000000000000298
   Web of Science ®Google Scholar
• Harel-Adar T, Ben MT, Amsalem Y, Feinberg MS, Leor J, Cohen S. Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair. Proc Natl Acad Sci. 2011;108:1827–1832. doi:10.1073/pnas.1015623108
   PubMed Web of Science ®Google Scholar
• Kawai T, Elliott KJ, Scalia R, Eguchi S. Contribution of ADAM17 and related ADAMs in cardiovascular diseases. Cell Mol Life Sci. 2021;78:4161–4187. doi:10.1007/s00018-021-03779-w
   Web of Science ®Google Scholar
• Bevers EM, Williamson PL. Getting to the outer leaflet: physiology of phosphatidylserine exposure at the plasma membrane. Physiol Rev. 2016;96:605–645. doi:10.1152/physrev.00020.2015
   PubMed Web of Science ®Google Scholar
• Morel O, Jesel L, Freyssinet J-M, Toti F. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol. 2011;31:15–26. doi:10.1161/ATVBAHA.109.200956
   PubMed Web of Science ®Google Scholar
• Owens AP, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res. 2011;108:1284–1297. doi:10.1161/CIRCRESAHA.110.233056
   PubMed Web of Science ®Google Scholar
• Groth E, Pruessmeyer J, Babendreyer A, et al. Stimulated release and functional activity of surface expressed metalloproteinase ADAM17 in exosomes. Biochim Biophys Acta Mol Cell Res. 2016;1863:2795–2808. doi:10.1016/j.bbamcr.2016.09.002
   Web of Science ®Google Scholar
• Cappellano G, Raineri D, Rolla R, et al. Circulating platelet-derived extracellular vesicles are a hallmark of Sars-Cov-2 infection. Cells. 2021;10:85. doi:10.3390/cells10010085
   Web of Science ®Google Scholar
• Rausch L, Lutz K, Schifferer M, et al.Binding of phosphatidylserine-positive microparticles by PBMCs classifies disease severity in COVID-19 patients. bioRxiv Prepr. 2021. doi:10.1002/jev2.12173
   Google Scholar
• Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pohlmann S. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol. 2014;88:1293–1307. doi:10.1128/JVI.02202-13
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280.e8. doi:10.1016/j.cell.2020.02.052
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Hofmann-Winkler H, Pöhlmann S. Priming time: how cellular proteases arm coronavirus spike proteins. In: Act Viruses by Host Proteases. Cham: Springer International Publishing;2018:71–98. doi:10.1007/978-3-319-75474-1_4
   Google Scholar
• Yeung ML, Teng JLL, Jia L, et al. Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system. Cell. 2021;184:2212–2228.e12. doi:10.1016/j.cell.2021.02.053
   PubMed Web of Science ®Google Scholar
• Lundström A, Ziegler L, Havervall S, et al. Soluble angiotensin‐converting enzyme 2 is transiently elevated in COVID‐19 and correlates with specific inflammatory and endothelial markers. J Med Virol. 2021;93:5908–5916. doi:10.1002/jmv.27144
   PubMed Web of Science ®Google Scholar
• Epelman S, Tang WHW, Chen SY, Van Lente F, Francis GS, Sen S. Detection of soluble angiotensin-converting enzyme 2 in heart failure. J Am Coll Cardiol. 2008;52:750–754. doi:10.1016/j.jacc.2008.02.088
   PubMed Web of Science ®Google Scholar
• Driscoll WS, Vaisar T, Tang J, Wilson CL, Raines EW. Macrophage ADAM17 deficiency augments CD36-dependent apoptotic cell uptake and the linked anti-inflammatory phenotype. Circ Res. 2013;113:52–61. doi:10.1161/CIRCRESAHA.112.300683
   PubMed Web of Science ®Google Scholar
• Schweigert O, Dewitz C, Möller-Hackbarth K, et al. Soluble T cell immunoglobulin and mucin domain (TIM)-1 and −4 generated by A Disintegrin And Metalloprotease (ADAM)-10 and −17 bind to phosphatidylserine. Biochim Biophys Acta Mol Cell Res. 2014;1843:275–287. doi:10.1016/j.bbamcr.2013.11.014
   Web of Science ®Google Scholar
• de Queiroz TM, Lakkappa N, Lazartigues E. ADAM17-mediated shedding of inflammatory cytokines in hypertension. Front Pharmacol. 2020;11. doi:10.3389/fphar.2020.01154
   Web of Science ®Google Scholar
• Tajbakhsh A, Gheibi Hayat SM, Butler AE, Sahebkar A. Effect of soluble cleavage products of important receptors/ligands on efferocytosis: their role in inflammatory, autoimmune and cardiovascular disease. Ageing Res Rev. 2019;50:43–57. doi:10.1016/j.arr.2019.01.007
   PubMed Web of Science ®Google Scholar
• Schönrich G, Raftery MJ. The PD-1/PD-L1 axis and virus infections: a delicate balance. Front Cell Infect Microbiol. 2019;9. doi:10.3389/fcimb.2019.00207
   Web of Science ®Google Scholar
• Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18:153–167. doi:10.1038/nri.2017.108
   PubMed Web of Science ®Google Scholar
• Orme JJ, Jazieh KA, Xie T, et al. ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. Oncoimmunology. 2020;9. doi:10.1080/2162402X.2020.1744980
   Web of Science ®Google Scholar
• Zhu X, Lang J. Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. Oncotarget. 2017;8:97671–97682. doi:10.18632/oncotarget.18311
   PubMedGoogle Scholar
• Bailly C, Thuru X, Quesnel B. Soluble programmed death ligand-1 (sPD-L1): a pool of circulating proteins implicated in health and diseases. Cancers (Basel). 2021;13:3034. doi:10.3390/cancers13123034
   Web of Science ®Google Scholar
• Sabbatino F, Conti V, Franci G, et al. PD-L1 dysregulation in COVID-19 patients. Front Immunol. 2021;12. doi:10.3389/fimmu.2021.695242.
   Web of Science ®Google Scholar
• dos-Santos D, Salina AC, Rodrigues TS, et al. Efferocytosis of SARS-CoV-2-infected dying cells impairs macrophage anti-inflammatory programming and continual clearance of apoptotic cells. MedRixv. 2021. doi:10.1101/2021.02.18.21251504
   Google Scholar
• Gupta S, Hayek SS, Wang W, et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med. 2020;180:1436. doi:10.1001/jamainternmed.2020.3596
   PubMed Web of Science ®Google Scholar
• Sandoval M, Nguyen DT, Vahidy FS, Graviss EA. Risk factors for severity of COVID-19 in hospital patients age 18–29 years. PLoS One. 2021;16:e0255544. doi:10.1371/journal.pone.0255544
   Web of Science ®Google Scholar
• Burrage DR, Koushesh S, Sofat N. Immunomodulatory drugs in the management of SARS-CoV-2. Front Immunol. 2020;11. doi:10.3389/fimmu.2020.01844
   Web of Science ®Google Scholar
• The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704. doi:10.1056/NEJMoa2021436
   PubMed Web of Science ®Google Scholar
• McColl A, Bournazos S, Franz S, et al. Glucocorticoids induce protein S-dependent phagocytosis of apoptotic neutrophils by human macrophages. J Immunol. 2009;183:2167–2175. doi:10.4049/jimmunol.0803503
   PubMed Web of Science ®Google Scholar
• Ehrchen J, Steinmüller L, Barczyk K, et al. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood. 2007;109:1265–1274. doi:10.1182/blood-2006-02-001115
   PubMed Web of Science ®Google Scholar
• Lauber K, Keppeler H, Munoz LE, et al. Milk fat globule-EGF factor 8 mediates the enhancement of apoptotic cell clearance by glucocorticoids. Cell Death Differ. 2013;20:1230–1240. doi:10.1038/cdd.2013.82
   PubMed Web of Science ®Google Scholar
• Fernandez-Boyanapalli RF, Falcone EL, Zerbe CS, et al. Impaired efferocytosis in human chronic granulomatous disease is reversed by pioglitazone treatment. J Allergy Clin Immunol. 2015;136:1399–1401.e3. doi:10.1016/j.jaci.2015.07.034
   PubMed Web of Science ®Google Scholar
• Erol A. Role of oxidized LDL-induced “trained macrophages” in the pathogenesis of COVID-19 and benefits of pioglitazone: a hypothesis. Diabetes Metab Syndr Clin Res Rev. 2020;14:713–714. doi:10.1016/j.dsx.2020.05.007
   Web of Science ®Google Scholar
• Zizzo G, Cohen PL. The PPAR-γ antagonist GW9662 elicits differentiation of M2c-like cells and upregulation of the MerTK/Gas6 axis: a key role for PPAR-γ in human macrophage polarization. J Inflamm. 2015;12(1):36. doi:10.1186/s12950-015-0081-4.
   Google Scholar
• Fernandez-Boyanapalli R, Frasch SC, Riches DWH, Vandivier RW, Henson PM, Bratton DL. PPARγ activation normalizes resolution of acute sterile inflammation in murine chronic granulomatous disease. Blood. 2010;116:4512–4522. doi:10.1182/blood-2010-02-272005
   PubMed Web of Science ®Google Scholar
• Agrawal S, Chanley MA, Westbrook D, et al. Pioglitazone enhances the beneficial effects of glucocorticoids in experimental nephrotic syndrome. Sci Rep. 2016;6:24392. doi:10.1038/srep24392
   Web of Science ®Google Scholar
• Calligaris M, Cuffaro D, Bonelli S, et al. Strategies to target ADAM17 in disease: from its discovery to the iRhom revolution. Molecules. 2021;26:944. doi:10.3390/molecules26040944
   Web of Science ®Google Scholar
• Lartey NL, Valle-Reyes S, Hilda Vargas-Robles KE, et al. ADAM17 inhibition prevents neutrophilia and lung injury in a mouse model of Covid-19. bioRxiv Prepr. 2021. doi:10.1002/JLB.3COVA0421-195RR
   Google Scholar
• Blaydon DC, Biancheri P, Di W-L, et al. Inflammatory skin and bowel disease linked to ADAM17 deletion. N Engl J Med. 2011;365:1502–1508.
   PubMed Web of Science ®Google Scholar
• Bandsma RHJ, van Goor H, Yourshaw M, et al. Loss of ADAM17 is associated with severe multiorgan dysfunction. Hum Pathol. 2015;46:923–928. doi:10.1016/j.humpath.2015.02.010
   Web of Science ®Google Scholar
• Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181:905–913.e7. doi:10.1016/j.cell.2020.04.004
   PubMed Web of Science ®Google Scholar
• Rahman MM, Hasan M, Ahmed A. Potential detrimental role of soluble ACE2 in severe COVID‐19 comorbid patients. Rev Med Virol. 2021;rmv.2213. doi:10.1002/rmv.2213
   Web of Science ®Google Scholar
• Zoufaly A, Poglitsch M, Aberle JH, et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir Med. 2020;8:1154–1158. doi:10.1016/S2213-2600(20)30418-5
   PubMed Web of Science ®Google Scholar
• Belzile O, Huang X, Gong J, et al. Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer. ImmunoTargets Ther. 2018;7:1–14. doi:10.2147/ITT.S134834
   Web of Science ®Google Scholar
• Dowall SD, Graham VA, Corbin-Lickfett K, et al. Effective binding of a phosphatidylserine-targeting antibody to Ebola virus infected cells and purified virions. J Immunol Res. 2015;2015:1–9. doi:10.1155/2015/347903
   Web of Science ®Google Scholar
• Soares MM, King SW, Thorpe PE. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat Med. 2008;14:1357–1362. doi:10.1038/nm.1885
   PubMed Web of Science ®Google Scholar
• Bevers EM, Janssen MP, Comfurius P, et al. Quantitative determination of the binding of β2-glycoprotein I and prothrombin to phosphatidylserine-exposing blood platelets. Biochem J. 2005;386:271–279. doi:10.1042/BJ20041167
   PubMed Web of Science ®Google Scholar
• Ho Y, Ahuja K, Körner H, Adams M. β2GP1, anti-β2GP1 antibodies and platelets: key players in the antiphospholipid syndrome. Antibodies. 2016;5:12. doi:10.3390/antib5020012
   Google Scholar
• Thomas JM, Thorpe PE. Protective effect of anti-phosphatidylserine antibody in a guinea pig model of advanced hemorrhagic arenavirus infection. Open Microbiol J. 2017;11:303–315. doi:10.2174/1874285801711010303
   Google Scholar
• Shao R, Xiong C, Wen X, Gelovani JG, Li C. Targeting phosphatidylserine on apoptotic cells with phages and peptides selected from a bacteriophage display library. Mol Imaging. 2007;6:7290.2007.00037. doi:10.2310/7290.2007.00037
   Web of Science ®Google Scholar
• Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls; 2021. Available from https://www.ncbi.nlm.nih.gov/books/NBK554776/.
   Google Scholar
• Kern DM, Sorum B, Mali SS, et al. Cryo-EM structure of SARS-CoV-2 ORF3a in lipid nanodiscs. Nat Struct Mol Biol. 2021;28:573–582. doi:10.1038/s41594-021-00619-0
   PubMed Web of Science ®Google Scholar
• Gupta S, Mallick D, Banerjee K, Sarkar S, Sonny TM, Partha basuchowdhuri SSJ. D155Y substitution of SARS-CoV-2 ORF3a weakens binding with caveolin-1: an in silico study. bioRxiv Prepr. 2021. doi:10.1101/2021.03.26.437194
   Google Scholar
• Padhan K, Tanwar C, Hussain A, et al. Severe acute respiratory syndrome coronavirus Orf3a protein interacts with caveolin. J Gen Virol. 2007;88:3067–3077. doi:10.1099/vir.0.82856-0
   Web of Science ®Google Scholar
• Chakraborty S, Mallajosyula V, Tato CM, Tan GS, Wang TT. SARS-CoV-2 vaccines in advanced clinical trials: where do we stand? Adv Drug Deliv Rev. 2021;172:314–338. doi:10.1016/j.addr.2021.01.014
   Web of Science ®Google Scholar
• Caddy SL, Vaysburd M, Papa G, et al. Viral nucleoprotein antibodies activate TRIM21 and induce T cell immunity. EMBO J. 2021;40. doi:10.15252/embj.2020106228
   Web of Science ®Google Scholar
• Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021;20:817–838. doi:10.1038/s41573-021-00283-5
   PubMed Web of Science ®Google Scholar
• Kunzelmann K. Getting hands on a drug for Covid-19: inhaled and intranasal niclosamide. Lancet Reg Health. 2021;4:100094.
   Google Scholar
• Defective efferocytosis as a predictor of COVID-19 mortality. OSF Preprints. 2021; September 131–18. doi:10.31219/osf.io/cfwsh
   Google Scholar